DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aralast ( Alpha 1-Antitrypsin) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

ARALAST drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

CONTRAINDICATIONS

ARALAST NP is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.

REFERENCES

  1. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha–1–antitrypsin deficiency. Am J Med 1988 (Suppl 6A);84:13–31.
  2. Data on file at Baxter Healthcare Corporation.
  3. Crystal RG, Brantly ML, Hubbard RC, Curiel DT, et al. The alpha1–antitrypsin gene and its mutations: Clinical consequences and strategies for therapy. Chest 1989;95:196–208.
  4. Crystal RG. α1–Antitrypsin deficiency: pathogenesis and treatment. Hospital Practice 1991;Feb.15:81–94.
  5. Hutchison DCS. Natural history of alpha–1–protease inhibitor deficiency. Am J Med 1988;84(Suppl 6A):3–12.
  6. Hubbard RC, Crystal RG. Alpha–1–antitrypsin augmentation therapy for alpha–1– antitrypsin deficiency. Am J Med 1988;84(Suppl 6A):52–62.
  7. Buist SA, Burrows B, Cohen A, et al. Guidelines for the approach to the patient with severe hereditary alpha–1–antitrypsin deficiency. Am Rev Respir Dis 1989;140:1494–1497.
  8. Gadek JE, Fells GA, Zimmerman RL, et al. Antielastases of the human alveolar structures: Implications for the protease-antiprotease theory of emphysema. J Clin Invest 1981;68:889-898.
  9. Stoller JK, Brantly M, Fleming LE, et al. Formation and current results of a patient-organized registry for α1–antitrypsin deficiency. Chest 2000; 118(3):843-848.
  10. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of α1-antitrypsin deficiency. Chest 1997;111:394-403.
  11. FDA/CBER “Heterogeneity of Alpha-1-Proteinase Inhibitor Products” 27 Mar 2006 <http://www.fda.gov/cber/infosheets/alph1pi.htm>
  12. Kolarich D, et al. Biochemical, molecular characterization, and glycoproteomic analyses of α1-proteinase inhibitor products used for replacement therapy. Transfusion 2006;46:1959-1977.
  13. Transcript of Blood Products Advisory Committee (BPAC) 85th Meeting; 3-4 Nov 2005.
  14. Turino GM, Barker AF, Brantly ML, et al: Clinical features of individuals with Pi*SZ phenotype of α1-antitrypsin deficiency. Am J Respir Crit Care Med 154: 1718-25, 1996.

BAXTER and ARALAST NP are trademarks of Baxter International Inc.

U.S. Patent No.: 5,616,693; 5,981,715 Other U.S. Patents Pending

DATE OF REVISION: Apr 2010

Baxter Healthcare Corporation

Westlake Village, CA 91362

U.S. License No. 140

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015